[{"address1": "12278 Scripps Summit Drive", "city": "San Diego", "state": "CA", "zip": "92131", "country": "United States", "phone": "858 875 1800", "website": "https://www.fatetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 181, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bahram  Valamehr M.B.A., Ph.D.", "age": 46, "title": "President & CEO", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 644500, "exercisedValue": 0, "unexercisedValue": 13288}, {"maxAge": 1, "name": "Ms. Cindy R. Tahl J.D.", "age": 51, "title": "Chief Legal & Compliance Officer and Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 612500, "exercisedValue": 0, "unexercisedValue": 25250}, {"maxAge": 1, "name": "Dr. Jerome  Bressi Ph.D.", "title": "Chief Regulatory & Quality Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Henry", "age": 60, "title": "Senior Vice President of Clinical Operations", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 3, "compensationRisk": 10, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.4, "open": 1.39, "dayLow": 1.27, "dayHigh": 1.4, "regularMarketPreviousClose": 1.4, "regularMarketOpen": 1.39, "regularMarketDayLow": 1.27, "regularMarketDayHigh": 1.4, "beta": 1.879, "forwardPE": -0.7768107, "volume": 991362, "regularMarketVolume": 991362, "averageVolume": 3215643, "averageVolume10days": 1158170, "averageDailyVolume10Day": 1158170, "bid": 1.24, "ask": 1.31, "bidSize": 600, "askSize": 600, "marketCap": 159452304, "fiftyTwoWeekLow": 1.04, "fiftyTwoWeekHigh": 8.83, "priceToSalesTrailing12Months": 11.857835, "fiftyDayAverage": 1.8138, "twoHundredDayAverage": 3.13915, "currency": "USD", "enterpriseValue": -53296196, "floatShares": 98787389, "sharesOutstanding": 113894000, "sharesShort": 12698496, "sharesShortPriorMonth": 12186948, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.111499995, "heldPercentInsiders": 0.022809999, "heldPercentInstitutions": 1.00422, "shortRatio": 3.69, "shortPercentOfFloat": 0.1279, "impliedSharesOutstanding": 125553000, "bookValue": 3.181, "priceToBook": 0.3992455, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -178231008, "trailingEps": -1.49, "forwardEps": -1.68, "enterpriseToRevenue": -3.963, "enterpriseToEbitda": 0.324, "52WeekChange": -0.77742445, "SandP52WeekChange": 0.21027291, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "FATE", "underlyingSymbol": "FATE", "shortName": "Fate Therapeutics, Inc.", "longName": "Fate Therapeutics, Inc.", "firstTradeDateEpochUtc": 1380634200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "98fe3f7f-5aa9-30d5-b866-ea8a0474dc72", "messageBoardId": "finmb_39268712", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.27, "targetHighPrice": 10.0, "targetLowPrice": 3.0, "targetMeanPrice": 6.30769, "targetMedianPrice": 5.0, "recommendationMean": 2.44444, "recommendationKey": "buy", "numberOfAnalystOpinions": 13, "totalCash": 296923008, "totalCashPerShare": 2.607, "ebitda": -164668992, "totalDebt": 98978000, "quickRatio": 8.096, "currentRatio": 8.292, "totalRevenue": 13447000, "debtToEquity": 27.317, "revenuePerShare": 0.123, "returnOnAssets": -0.22106001, "returnOnEquity": -0.4659, "grossProfits": -108861000, "freeCashflow": -58500376, "operatingCashflow": -131712000, "revenueGrowth": 0.581, "operatingMargins": -17.03871, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]